RecruitingSARS-CoV InfectionCOVID-19
Mitoquinone/Mitoquinol Mesylate as Oral and Safe Postexposure Prophylaxis for Covid-19
Eligible age
18–65 yrs
Accepts
All genders
Locations
1 state
Healthy volunteers
Yes
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
Adults who do not have major health, kidney, gastrointestinal disease will be randomized to receive oral mitoquinone/mitoquinol mesylate (Mito-MES) versus placebo to prevent the development and progression of COVID-19 after high-risk exposure to a person with confirmed SARS-CoV-2 infection.
Sponsor: University of Texas Southwestern Medical Center
You may qualify if…
- ✓ Age 18-65 years old Asymptomatic (no symptoms of viral infection) on study entry High risk exposure without use of masks to confirmed case of COVID-19 Members in a household one of which is a confirmed case of COVID-19 Negative baseline SARS-COV-2 diagnostic test
You may not qualify if…
- ✕ Women with variations in physiological functions due to hormones that may effect immune function and (transgender, pregnant, breastfeeding)
- ✕ Specific significant clinical diseases \[cardiovascular disease (such as coronary artery/vascular disease), heart disease (such as congestive heart failure, cardiomyopathy, atrial fibrillation), lung disease (such as chronic obstructive pulmonary disease, asthma, bronchiectasis, pulmonary fibrosis, pleural effusions), kidney disease (glomerular filtration rate or GFR less than 60 ml/min/1.73 m2), liver disease (such as cirrhosis, hepatitis), major immunosuppression (such as history of transplantation, uncontrolled HIV infection, cancer on active chemotherapy\] based on history. Participants with well controlled HIV (CD4 count \> 500 cells/mm\^3 and HIV viral load \< 50 copies/ml) and people with remote history of cancer not on active treatment will be allowed to participate.
- ✕ History of known gastrointestinal disease (such as gastroparesis) that may predispose patients to nausea
- ✕ History of auto-immune diseases
- ✕ Chronic viral hepatitis
- ✕ Use of systemic immunomodulatory medications (e.g. steroids) within 4 weeks of enrollment
- ✕ Any participant who has received any investigational drug within 30 days of dosing
- ✕ History of underlying cardiac arrhythmia
Where it's recruiting
Texas
Dallas
Source: ClinicalTrials.gov · NCT05886816 · last updated 2026-03-16